A genetically modified herpes simplex virus that has utility as a drug screening tool

The Portal is a joint project of MATTO and the MTTC. The development and implementation of the portal has been paid for by the MTTC, Beth Israel Deaconess Medical Center, Boston Biomedical Research Institute, Boston University, Brandeis University, Caritas St. Elizabeth's Medical Center, Boston Children's Hospital, Dana Farber Cancer Institute, Harvard University, Joslin Diabetes Center, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, McLean Hospital, Northeastern University, The Schepens Eye Research Institute, and Tufts University.

Intellectual Property

ID:		1546
IP Type:		Licensable Technology
Title:		A genetically modified herpes simplex virus that has utility as a drug screening tool
Inventor:		Knipe, David M.
Summary:		MARKETS ADDRESSED: Antiviral drug screen INNOVATIONS & ADVANTAGES: Harvard Medical School researchers have developed a genetically modified herpes simplex virus that has utility as a drug screening tool. To develop this tool, Harvard researchers engineered a replication competent herpes virus that contains green fluorescent protein (GFP) fused to a viral replication protein. During replication, this modified protein is transcribed and translated such that its expression can be detected by fluorescence of the GFP. As a result, drug candidates that affect herpes replication or the expression of this protein can be identified by changes in the level of fluorescence.
Tech Type:
URL:		http://otd.harvard.edu/technologies/tech.php?case=1546
Contact:		Michal Preminger, (617) 432-0920
Organization:		Harvard University

Display all intellectual properties for Knipe, David M.
Display all intellectual properties for Harvard University